Novartis to conduct a study with bimagrumab in obese adults with type 2 diabetes

MorphoSys AG announced that its partner Novartis will conduct a phase II clinical trial designed to assess bimagrumab in obese patients with type 2 diabetes. According to information published on, the study will enroll 60 patients in order to assess the safety, pharmacokinetics and efficacy of intravenous bimagrumab vs placebo. It will measure the change in fat body mass at weeks 24 and 48. Other endpoints will evaluate parameters such as glycaemia monitoring and insulin resistance.
(Source Business Wire)